Treatment of disseminated intravascular coagulation with gabexate mesilate.

Abstract

Gabexate mesilate (FOY) was used to treat 215 patients with disseminated intravascular coagulation (DIC) and 146 patients with a predisposition to DIC (pre-DIC). Sixty percent of DIC patients and 48% of pre-DIC patients exhibited pretreatment organ failure, which resolved after FOY treatment in 16% of DIC patients and 17% of pre-DIC patients. Seventy percent of DIC patients and 49% of pre-DIC patients had a pretreatment bleeding tendency that was ameliorated by FOY treatment in 32% of DIC patients and 30% of pre-DIC patients. Comparison of pretreatment and posttreatment hemostatic studies of the DIC patients revealed that platelet count and levels of fibrinogen degradation products (FDP), thrombin-antithrombin-III complex, and FDP-D-dimer decreased significantly; fibrinogen level increased markedly; and prothrombin time was prolonged. DIC scores were significantly lowered in both leukemic and nonleukemic patients from the third day of treatment with FOY. Among leukemic DIC patients, 59% showed complete remission (CR), 21% partial remission (PR), and 7% exacerbation of their condition; 46% of the nonleukemic DIC patients demonstrated CR, 17% PR, and 17% exacerbation. Of the leukemic pre-DIC patients, 59% showed improvement and 7% exacerbation, whereas 55% of the nonleukemic pre-DIC patients showed improvement and 27% exacerbation.

• Authors: S Tamaki, H Wada, K Hiyoyama, M Shimura, K Minamikawa, Y Wakita, T Nakase, M Ohiwa, T Kaneko, E Iwasaki
• Journal: Clinical therapeutics (Clin Ther) 1993 Nov-Dec Vol. 15 Issue 6 Pg. 1076-84 ISSN: 0149-2918 [Print] United States
• PMID: 8111805 (Publication Type: Journal Article)

Chemical References

• Gabexate

Topics

• Disseminated Intravascular Coagulation (drug therapy)
• Female
• Gabexate (therapeutic use)
• Humans
• Male
• Thrombosis (complications)